Current concepts of metastasis in melanoma (original) (raw)

. Author manuscript; available in PMC: 2009 Aug 1.

Published in final edited form as: Expert Rev Dermatol. 2008 Oct;3(5):569–585. doi: 10.1586/17469872.3.5.569

Abstract

The main cause of death in melanoma patients is widespread metastases. Staging of melanoma is based on the primary tumor thickness, ulceration, lymph node and distant metastases. Metastases develop in regional lymph nodes, as satellite or in-transit lesions, or in distant organs. Lymph flow and chemotaxis is responsible for the homing of melanoma cells to different sites. Standard pathologic evaluation of sentinel lymph nodes fails to find occult melanoma in a significant proportion of cases. Detection of small numbers of malignant melanoma cells in these and other sites, such as adjacent to the primary site, bone marrow or the systemic circulation, may be enhanced by immunohistochemistry, reverse transcription PCR, evaluation of lymphatic vessel invasion and proteomics. In the organs to which melanoma cells metastasize, extravasation of melanoma cells is regulated by adhesion molecules, matrix metalloproteases, chemokines and growth factors. Melanoma cells may travel along external vessel lattices. After settling in the metastatic sites, melanoma cells develop mechanisms that protect them against the attack of the immune system. It is thought that one of the reasons why melanoma cells are especially resistant to killing is the fact that melanocytes (cells from which melanoma cells derive) are resistant to such noxious factors as ultraviolet light and reactive oxygen species. Targeted melanoma therapies are, so far, largely unsuccessful, and new ones, such as adjuvant inhibition of melanogenesis, are under development.

Keywords: biotherapy, chemokine, integrin, melanoma, metastasis, sentinel lymph node

Melanoma occurrence, staging & detection

Before we review several concepts related to mechanisms of melanoma metastasis and treatment, we will briefly describe the currently available data about melanoma occurrence, the currently used system that divides melanoma patients into groups with different survival rates and the methods used to detect melanoma cells beyond the primary cutaneous tumor site. The American Cancer Society predicted that 59,940 new cases of melanoma occurred in 2007 (4% of all cancer cases). Of those cases, 8100 patients (13%) died, predominantly because of widespread metastases (1–2% of all cancer deaths) [201]. The Melanoma Staging Committee of the American Joint Committee on Cancer established a new evidence-based staging system for cutaneous melanoma in 2003 [1]. These criteria have subsequently been approved by several entities including the Union Against Cancer/Union International Contre le Cancer TNM (tumor, lymph nodes and metastsis) Committee, the WHO Melanoma Program and the European Organization for Research and Treatment of Cancer Melanoma Group [1]. Stages I and II of this system are comprised of patients without regional or distant metastases. Stage III patients have metastases either in the regional lymph nodes or in intralymphatic sites (further defined as satellite or in-transit). Stage IV patients have metastases in distant sites. Survival of patients in all groups depends on different predictors. The thickness and ulceration of melanomas are important criteria in assessing survival in patients with localized disease (stages I and II) (Figure 1). Patients with the least advanced disease (other than melanoma in situ), that is, in stage IA disease (i.e., T1aN0M0, lesion less than 1 mm thick, without ulceration and extending into reticular dermis [Clark level II/III]) have a 94% 5-year and an 86% 10-year survival. Patients with stage IIC disease (i.e., T4bN0M0, lesion more than 4 mm thick with ulceration) have a 53% 5-year and a 41% 10-year survival [1]. The number of metastatic lymph nodes and the overall quantity of neoplastic cells are greatest in patients with stage III disease (Figure 2). Specifically, detection of lymph nodes by palpation as opposed to detection of neoplastic cells in lymph nodes by light microscopy was linked to a shorter survival. Patients with stage IIIA disease (i.e., T1–4aN1a-2aM0, lesion of any thickness, without ulceration, with microscopic metastasis) have a 67% 5-year survival rate. Patients with stage IIIC disease (any TN3M0, four or more metastatic lymph nodes, matted lymph nodes, in-transit metastasis with metastatic lymph nodes) have a 28% 5-year survival rate (Figure 3) [2]. In patients with stage IV disease, the site of metastasis and level of lactate dehydrogenase are the most important predictors of survival. Patients that have metastases to distant skin or subcutanesous sites or distant lymph nodes are categorized in group M1a. These patients have a 1-year survival rate of 59%. Patients with metastases to the lungs are categorized in group M1b and have a 1-year survival rate of 57%. Patients with metastases to any other visceral sites have the worst prognosis with a 1-year survival rate of 41% [2]. Two or more elevated lactate dehydrogenase levels drawn more than 24 h apart will upgrade a patient to group M1c, regardless of the site of metastases. Of note, the number of metastases, although previously recognized as a prognostic determinant, is not incorporated as part of the current staging system. This is due to existing differences, such as lack of standardization of imaging modalities in different centers [1].

Figure 1. Breslows tumor thickness and ulceration are currently the American Joint Committee on Cancer criteria for staging of primary cutaneous melanoma and the most predictive factor for occult metastasis at the time of diagnosis.

Figure 1

Figure 2. Histologic and clinical findings that classify the tumor as American Joint Committee on Cancer stage III.

Figure 2

(A) Microscopic, immunohistochemistry positive (MART1) sentinel lymph node, (B) clinically and pathogically positive lymph node and (C) peritumoral and in transit metastasis (right).

Figure 3. Factors that are predictive of metastasis in the primary.

Figure 3

(A) Mitotic rate, (B) vascular invasion, (C) absence of a tumor-infiltrating lymphocyte host response and (D) microsatellites, whose presence upgrades the melanoma to American Joint Committee on Cancer stage IIIc and are essentially in-transit metastasis.

Since metastasis is the most important predictor of the patient's prognosis, there is a lot of effort directed at unequivocal determination of their presence in the adjacent epidermis, sentinel lymph nodes, circulation and distant sites (Box 1).

Box 1. Detection of melanoma: summary of different aspects of occult melanoma detection.

Aspect:
• ‘Field cells’ detection [3,4]
• Local lymphatic invasion [5–7]
• Sentinel lymph node [8]
• Sentinel lymph node with reverse transcription PCR [9–12]
• Microarray analysis [13]
• Immune environment in the sentinel lymph node [17–20]
• Circulating melanoma cells [21–29]
• Proteomic analysis [35]
• Imaging studies [36–41]

Before melanoma cells metastasize they extend into the adjacent epidermis. ‘Field cells’ were characterized by Bastian et al. [3]. Epidermis adjacent to the acral lentiginous melanoma can harbor cells with a high level of DNA amplifications (11q13, 5p15) that can be detected by fluorescent in situ hybridization. Genetic analysis of these cells suggests that they precede melanoma in situ. They also extend significantly into normal skin without a correlation to tumor thickness or size [4].

Another potential step in the evolution of a primary tumor into its metastasis to lymph nodes is local lymphatic invasion. This is usually only assessed in the excisions of the primary tumor on hematoxylin and eosin slides. In a recent study, immunohistochemical stains with antibodies against podoplanin (specific for lymphatic vessels) and S-100 (specific for melanoma) [5] were combined with multispectral imaging analysis. This increased the sensitivity of detection of lymphatic invasion sevenfold. Dadras et al. used the antibody against lymphatic endothelial hyaluronan receptor (LYVE)-1 to decorate lymphatic vessels in the tumor and its close proximity (within 100 μm) to its border [6]. Additionally, they assessed expression of VEGF-C and VEGF-D in melanomas. As it turned out, VEGF-C and not VEGF-D correlated with a higher frequency of melanoma metastases to sentinel lymph nodes. The relative area of vascular invasion of primary melanomas [7] correlated with metastasis to sentinel lymph nodes to a greater extent (p = 0.00008) than did tumor thickness (p = 0.005), as determined by the Wilcoxon rank test.

The choice of which lymph nodes to dissect by the method of elective lymph node dissection was based on the fact that patients with similar tumors presented with metastases in certain regional locations. This approach resulted in patients being overtreated and significant unnecessary morbidity. Sentinel lymph node biopsy is based on the pre- and intraoperative radiological imaging and injection of a marker dye that is distributed towards the closest lymph node that might harbor metastasis. The multicenter Selective Lymphadenectomy Trial-1 (MLST-1) has assessed the validity of this approach. In the MLST-1, 2001 patients with primary cutaneous melanomas greater than 1 mm in thickness and a Clark's level III stage or greater, or less than 1 mm in thickness and at least a Clark's level IV stage, were randomly divided into two groups. Patients in the first group underwent a wide excision of their tumors and their clinical status was subsequently observed. Patients in the second group underwent wide excision of their tumors with sentinel lymph node biopsy followed by a complete lymph node dissection if metastasis was found in the sentinel lymph node. The first interim results of this trial were published in 2006 [8]. The mean estimated 5-year disease-free survival rate for the population was 78.3 ± 1.6% in the biopsy group and 73.1 ± 2.1% in the observation group (hazard ratio [HR] for recurrence [corrected]: 0.74; 95% confidence interval [CI]: 0.59–0.93; p = 0.009). Further analysis of MLST-1 are awaited and a new MLST-2 project has been initiated. The goals of the MLST-2 project are to discover if complete lymph node dissection is necessary after positive sentinel lymph node and, also, whether the determination of melanoma-specific mRNAs by RT-PCR in the sentinel lymph nodes correlates with an unfavorable prognosis in the patients [9]. According to systematic review and meta-analysis by Mocellin et al., positive reverse transcription PCR status correlated with both TNM stage (stage I or II vs III; PCR positivity, 95.1 vs 46.6%; p < 0001) and disease recurrence (PCR positive vs negative; relapse rate, 16.8 vs 8.7%; p < 0001). PCR positivity was also associated with a worse overall prognosis (HR: 5.08; 95% CI: 1.83–14.08; p = 002) and disease-free survival (HR: 0.41; 95% CI: 1.86–6.24; p < 0.0001) [10]. There is much debate and ongoing research regarding the molecular approach to the sentinel lymph node diagnosis. Several studies indicate that approximately 10% of sentinel lymph node-negative (as determined by hematoxylin and eosin and immunohistochemical staining) patients may experience local or widespread metastases [11]. A recent article presents results of combined studies of sentinel lymph nodes by three techniques: staining with hematoxylin and eosin, staining with antibodies against S-100 and HMB-45, and detection of tyrosinase mRNA by RT-PCR [12]. In this study, the 45 patients who were negative for melanoma by all three techniques did not have a recurrence in over 2 years of follow-up. Nevertheless, a very limited number of patients were studied (60 individuals). The conceptual problem related to the detection of tyrosinase and Melan-A by RT-PCR is that these genes are expressed by both melanoma and nevus cells. In addition, melanoma cells express different antigens with variable intensity. There is an effort to find antigens that would make RT-PCR both more sensitive and specific. Analysis of multiple markers (tyrosinase, melanoma antigen recognized by T cell [MART]-1, tyrosinase-related protein [TRP]1, TRP2, melanoma antigen [MAGE]-3, _N_-acetylgalactosaminyltransferase, Pax3, glycoprotein [gp]100 [10]) is one approach to increase sensitivity. Microarray technology has been employed to find new and possibly more specific antigens. Soikelli et al. identified 22 genes that differentiated lymph nodes in patients without melanoma from sentinel lymph nodes in patients with melanoma [13]. Subsequent prospective studies of Melan-A and tyrosinase expression confirmed their possible significance in the determination of patients' survival. Moreover, osteopontin (SPP1) and preferentially expressed antigen in melanoma (PRAME) were identified as melanoma-specific markers that differentiate melanoma cells from nevus cells in the sentinel lymph nodes. SPP1 is a phosphoprotein that binds CD44 and integrins, and regulates cell growth, adhesion, motility and angiogenesis [14]. PRAME is a melanoma-associated antigen recognized by cytotoxic lymphocytes [15]. Its function is unknown and, although it was discovered several years ago, it is still not used for differential diagnosis between benign and malignant melanocytic lesions. Proteins such as Skp2 and p27(kip1), which are implicated in melanoma progression, are another possibility [16]. The other potential proteins that may be used for sentinel lymph node study may include those that characterize their immunological microenvironment (i.e., expression of pro- and anti-inflammatory cytokines). Expression levels of IL-13, leptin, lymphotoxin-β receptor and macrophage inflammatory protein (MIP)1b is significantly higher, and expression level of IL-11Ra is lower in melanoma-positive compared with melanoma-negative sentinel lymph nodes [17]. Determination of the level of expression of these genes may aid in the assessment of sentinel lymph nodes. The other possibility is the expression of OX40 (CD134) on sentinel lymph node CD4 T cells. Expression of this gene decreased with more advanced features (e.g., thickness and ulceration) of primary cutaneous melanoma [18]. Immune cells and mediators also offer a possible explanation as to why melanoma cells mainly metastasize via of the lymphatic system. It is known that melanoma cells themselves are highly immunogenic. The immune system must be suppressed locally or systemically before metastases will develop. Patients with advanced melanoma have a high percentage of FOXp3-positive, IL-10-producing Treg lymphocytes [19]. It is possible that melanoma cells produce cytokines, such as TGFβ2, which might convert peripheral dendritic cells into cells with a tolerant phenotype [20]. These cells would migrate towards lymph nodes that neighbor the primary site of cutaneous melanoma. Lymph nodes with such an immunotolerant microenvironment would be natural harbors of spreading melanoma cells.

Molecular technology not only allows for more sensitive and specific assessment of sentinel lymph nodes, but also makes it possible to detect cancer cells in the circulation. The sole fact of the existence of circulating cancer cells seems to be only one of the prerequisites for the development of metastasis; nevertheless, it seems to be an important one. Markers used to detect circulating melanoma cells used in different studies included tyrosine, Melan-A, MAGE-3, melanoma cell-adhesion molecule-18, p97 and gp100 [21–24]. Most of these studies (∼60%) [22] found a correlation between the presence of circulating melanoma cells and poor outcome in the patients. Already, measurement of tyrosinase mRNA levels was a significant adverse prognostic factor for disease-free survival [25]. Several markers, such as Melan-A, gp100, MAGE-3, melanoma-inhibiting activity (MIA) and tyrosinase were used in the studies by Arenberger et al. [26]. Of those, MAGE-3 correlated the best with disease progression. Three markers were detected in 39% of the patients as opposed to one marker in 33% of the patients during disease progression. MAGEA-plex, MART-1 and tyrosinase delineated circulating melanoma cells most efficiently in studies by Xi et al. [27] because they had at least a 1000-fold higher expression in the melanoma cells within the peripheral blood. Of note, new methods are being developed that might allow for more effective yield of cancer cells from blood [28]. In addition, it seems that not the number of circulating single tumor cells but rather cell clusters correlate with the development of metastases [29]. Hence, PCR methods might not correlate as well with the development of metastases as previously thought.

Adequacy of several proteins is also being tested as markers of melanoma progression. TA90 immune complex (TA90IC) and MIA protein predicted survival in patients with stage III disease [30]. There are conflicting data regarding the usefulness of S-100β [30,31]. VEGF, VEGF receptor (VEGFR)1, TGF-β1 and Bcl-2 but not matrix metalloprotease (MMP)-3, angiogenin or VEGFR2 in serum correlated in some way with advancing stages in melanoma [32–34]. Proteomic analyses offer a promising alternative. In a study by Mian et al., 82% of samples from patients with stage III disease were correctly identified as having been derived from high-risk patients [35].

Search for the distant metastases in patients includes physical examination, chest radiography, ultrasonography, computed tomography (CT), MRI, lymphoscintigraphy and PET. (18F) fluorodeoxyglucose used in PET marks malignant cells. Malignant cells accumulate glucose as a result of upregulation of glucose transport (GLUT) molecules on their surface (such as GLUT1) [36]. PET has a superior role in the detection of distant metastases in all sites, except the thorax, iliac lymph nodes, subcutis and psoas muscle [37,38]. It has an overall 74% sensitivity and 67% specificity [37]. Concurrent PET and CT, especially with dedicated CT interpretation increases sensitivity to 98% and specificity to 94% [38]. New methods of detection of metastases were developed, such as melanin-inversion recovery imaging [39]. Radioactively labeled α-melanocyte-stimulating hormone (MSH) (203Pb, 99m cytotoxic T lymphocyte or 111In) may be an alternative probe to use for the detection of distant metastases [40,41].

Mechanisms of metastasis

It is generally believed that a neoplastic process progresses through several stages: tumor initiation, progression, invasion and then metastasis. Mechanisms of tumor (including melanoma) initiation and progression are reviewed elsewhere [42–44]. Of note, recent attention of the scientific (including melanoma) community shifted from progressive changes of neoplastic clones (accumulation of new mutations leading to more aggressive phenotypes) to the concept of neoplastic stem cells (Figure 4) [45–47]. According to this theory, tumors harbor stable stem cells that give rise to subsequent progeny. Stem cells would thus provide an attractive target for antineoplastic therapies. The actual initiating event of metastasis is not known. One concept suggests that the fusion of cancer cells with macrophages or other migratory bone marrow-derived cells underlies metastasis [48]. Fusion would result in activation of master regulatory genes that activate multiple pathways, particularly related to epithelial–mesenchymal transition, such as SNAIL, SLUG, SPARC and TWIST. Electron microscopy studies of spontaneous PADA melanoma showed that melanin is located in autophagosomes and not in the cytoplasm, as it is normally packaged in the melanocytes [49]. This provides one of the many clues that cancer cells can acquire the phenotype of macrophages.

Figure 4. Melanomas are characterized (similar to most metastatic tumors) as a heterogenous population of tumor cells that are genetically unstable and lead to clonal divergence and acquisition of metastatic phenotype.

Figure 4

A desmoplastic melanoma that developed a dark papule that lead to clinical and pathologic recognition is shown. The patient developed a lung metastasis with a similar population of cells.

The process of metastasis consists of several phases, as described by Nguyen and Massague [42], including vessel formation, evasion of immune surveillance, embolism, capillary adhesion, extravasation and organ-specific colonization. The spread of metastasis can occur through the vessel lumina, but also via extracellular lattices. Melanoma cells are characterized by an intrinsic, cell-specific phenotype inherited from their cells of origin. We will describe these phenomena more closely.

Routes of metastasis

Melanoma cells follow different patterns of metastatic spread. Some mechanisms responsible for interaction of melanoma cells with specific target organs have been elucidated. An excellent analysis was performed by the German Central Malignant Melanoma Registry, who recorded the data of patients treated in Tuebingen University Department of Dermatology in the years 1976–1996 [50]. Of the 3001 patients who presented with primary cutaneous melanoma, 466 developed metastases. Of these patients, 50% developed regional lymph node metastases, 22% developed satellite or in-transit metastases and 28% developed distant metastases, including distant skin metastases (Figure 5). Of the patients with distant metastases, 57% died. Of several possible risk factors (patient sex, age, tumor location, histology, thickness and level of invasion), primary tumor location predicted most strongly where metastases would develop. As a whole, primary melanomas metastasize most frequently to the regional lymph nodes. Tumors located in the extremities and trunk had the strongest predilection to develop satellite or in-transit metastases (Figure 6). Tumors located in the head and neck areas tended to develop metastases via all three routes. Statistical analyses showed certain gender-related predilections that were related to the actual primary melanoma site. Of interest, tumor thickness was also related to certain patterns of metastasis development. Tumors less than 0.76 mm and more than 1.5 mm thick developed preferentially satellite or in-transit metastases. Tumors of average thickness (0.75–1.5 mm) showed the highest rate of development of distant metastases. Time from initial presentation to the development of metastases was significantly longer for distant metastases. Accordingly, the mean period to development of distant metastases was 25 months, satellite/in-transit metastases was 17 months and lymph node metastases was 16 months. Other studies showed a similar distribution of routes of metastases and time of presentation [51–53].

Figure 5. Melanoma metastatic to subcutaneous tissue.

Figure 5

Distant subcutaneous melanoma metastases are a common phenomenon. Illustrated here is a well-circumscribed subcutaneous melanoma nodule from the scalp. Resection of distant metastases (metastatectomy), such as subcutaneous metastases, in selected melanoma patients is associated with improved 5-year survival [160].

Figure 6. In-transit melanoma metastasis of the lower extremity.

Figure 6

Extremity melanomas are often associated with a protracted course characterized by in-transit metastasis slowly progressing to the regional lymph node basin and beyond. The metastases can be epidermotropic and mimic a primary melanoma. Amputation of an acral melanoma of the first toe (top right panel) was followed by the acquisition of numerous ascending in-transit metastases, seen as small dark papules (top left panel and inset). Biopsy revealed well-defined superficial dermal nodules (bottom left panel) of melanoma cells abutting the epidermis (bottom right panel).

The old concept of ‘seed and soil’, that is, random dissemination of cancer cells, was recently challenged with the new concept of receptor–ligand interactions. How tumor cells reach lymphatic vessels is not yet fully elucidated [54]. Neoplastic cells may simply follow an interstitial pressure gradient or may secrete cytokines that induce growth of lymphatics towards the tumor or within the tumor. Tumor cells that invade the extracellular matrix (ECM) reach lymphatic vessels. Malignant cells then flow within the lymphatics to reach the subcapsular sinus of the lymph nodes. VEGF-R2 and VEGF-R3 are predominantly expressed on lymphatic endothelial cells. VEGF is a family of peptides that includes VEGF-A, VEGF-B, VEGF-C and VEGF-D, which bind to several receptors: VEGFR-1, VEGFR-2 and VEGFR-3. VEGF-C and VEGF-D, which bind to VEGFR-3, act on lymphatic endothelial cells to induce the production of lymphatic vessels [55]. It is known that melanoma cells can secrete VEGF-C, which induces lymphangiogenesis in the tumor [56]. However, only VEGFR tyrosine kinase inhibitors, and not antibodies (which target all VEGF receptors) reduced melanoma lymph node metastasis [57]. High VEGF-C levels in serum are related to deep lymph node involvement [58]. However, neither VEGFR-3 nor CD31 expression in primary cutaneous melanoma predicted lymph node involvement [59]. To our knowledge, there are no comprehensive studies to determine mechanisms or gene expression in melanomas that tend to metastasize to regional versus distant sites. Some melanomas express ligands/receptors that would cause preferential homing of melanoma cells to lymph nodes versus ligands/receptors associated with adherence of melanoma cells to tissues in distant sites. Chemokine/chemokine receptors and adhesion molecules are potential candidates of such ligand/receptor pairs. Chemokines are structurally related, small (8–14 kDa) polypeptide signaling molecules that activate serpentine G-protein-coupled receptors. The chemokine receptors are divided into CXC, CC, C and CX3C subgroups. Melanoma cells can express chemokine receptors chemokine (C-X-C motif) receptor (CXCR)4, CXCR7, CC-chemokine receptor (CCR)9, CCR10 and chemokines CXCL8, chemokine (C-X-C motif) ligand (CXCL)1–3, chemokine CC-ligand (CCL) 5 and CCL2 (Table 1) [60]. The study by Takeuchi et al. [61] showed a heterogeneous expression of CCR7 by melanoma cells. This receptor is normally expressed on naive T cells and dendritic cells. The CCL21/secondary lymphoid tissue chemokine (SLC) produced in lymph nodes causes homing of CCR7-bearing naive T cells and dendritic cells to the lymph nodes. In the aforementioned study, CCR7-bearing melanoma cells migrated preferentially in response to CCL21/SLC. The other potential chemokine/chemokine receptor is CXCL12 and CXCR4. The HR of melanoma relapse and death in patients whose melanoma cells expressed CXCR4 was 2.5 (95% CI: 1.2–6.1) as compared with patients with CXCR4-negative tumors [62]. The ligand for another chemokine receptor (CCR10) expressed on melanoma cells, CCL27, is expressed by normal keratinocytes and may stimulate melanoma development [63]. There is a difference in melanomas expressing different integrins. Melanomas that express integrin αvβ3 tend to develop lung metastases [64]. On the other hand, melanomas expressing integrin α4β1 develop lymph node metastases [65]. As far as distant metastases are concerned, expression of p75 NGF receptor (NGF-R) correlates with brain metastases and survival of brain-metastatic cell lines of epitheliod melanomas (Figure 7) [66]. NGF-R (low-affinity neurotrophin receptor) and TrkC (high-affinity neurotrophin receptor) are expressed in melanoma cells [66,67]. Their stimulation results in the enhancement of melanoma invasion through the stimulation of heparanase activity [68,69]. Axelsen et al. have identified thousands of genes that characterize normal tissues and different types of solid neoplasms (brain, breast, colon, endometrium, kidney, liver, lung, ovary, prostate, thyroid and melanoma) [70]. As expected, only a minority of genes were differentially expressed in cancers compared with their tissues of origin. Interestingly, different neoplasms were characterized by different levels of gene expression from normal tissues other than their tissue of origin. Melanomas expressed the highest number of genes that characterize the normal brain. This overexpression might contribute, in part, to the mechanism of metastases of melanoma to the brain, or just be related to the neural crest origin of melanomas [71]. Cutaneous melanoma metastasizes most commonly to the lungs (Figure 8) [72]. A single focus of pulmonary metastasis is associated with a better survival than the presence of multiple foci [73]. There are also data indicating that advanced age is associated with a better survival in mice with pulmonary metastasis as opposed to other sites of metastasis [74]. Tumor-doubling time might help determine which patients with pulmonary metastatic melanoma will benefit from surgery [75,76]. The liver is the most common (and often, the only) site of systemic metastasis of uveal melanoma [77]. Compared with normal melanocytes, uveal melanoma cells express more c-Met, IGF-IR and CXCR4. There is a high expression of corresponding ligands (HGF, IGF and CXCL12, respectively) in the liver [78]. Of all cancers, cutaneous melanoma is the most common type to metastasize to the submucosa of the small intestine (Figure 9) [79]. Migration to the small intestine is thought to be directed by CCL25, which is produced by the epithelium of the small intestine and attracts CCR9-bearing melanoma cells [80]. Integrin α4β1, but not β7, facilitates this process [80]. Examples of well-characterized receptor–ligand interactions in melanoma metastasis are summarized in Figure 10.

Table 1. Chemokines and melanoma: summary of chemokine/chemokine receptor pairs expressed on melanoma cells.

Chemokine receptor Chemokine Ref.
CCR7 CCL21/SLC [61]
CXCR4 CXCL12 [62,78]
CCR10 CCL27 [63]
CCR9 CCL25 [80]

Figure 7. Melanoma brain metastasis.

Figure 7

Brain metastases are common in melanoma and often hemorrhagic [161]. The top left panel depicts a cerebral metastases (top left) bordering a necrotic and hemorrhagic area (bottom right). The bottom left panel shows extravasated red blood cells and small vessels surrounding a nest of melanoma cells. The top right panel shows cerebral metastases (left side) adjacent to a large area of hemorrhage (right side). The bottom right panel illustrates both hemosiderin and hemorrhage in brain parenchyma.

Figure 8. Melanoma lung metastasis.

Figure 8

The lung is the most common sight of cutaneous melanoma visceral metastasis. Depicted in the left panel is replacement of most of the lung parenchyma by metastases. The top right panels shows the melanoma cells infiltrating alveolar spaces. The bottom right panel shows a metastasis with variable melanization of tumor cells.

Figure 9. Melanoma small intestine metastasis.

Figure 9

Metastasis to small intestine are rare and most often due to melanoma. The left panel shows submucosal small intestinal metastases. The right panel illustrates a small cluster of melanoma cells in the lamina propria.

Figure 10. Selected mechanisms of chemotaxis of melanoma cells to lymph nodes and distant organs.

Figure 10

Vessel formation

Formation of new vessels in primary and metastatic tumors is of extreme importance. This is thought to occur through the recapitulation of embryonic vessel formation (i.e., vasculogenic mimicry). This is defined more strictly as endothelial-like features being acquired by tumor cells. The tumor microenvironment, that is, interstitial fluid pressure, pH, cytokines, laminin, collagens, growth factors, nutrients and oxygen, is thought to stimulate angiogenesis through different mechanisms. Melanocytes of the epidermis are located in the milieu of decreased oxygen concentration which is thought to be responsible for their possible neoplastic transformation through stabilization of hypoxia-inducible factor (HIF)-1α and Akt-dependent pathway [81,82]. Hypoxia is known to increase expression of CXCR-4 on melanoma cells [83]. Vasculogenic mimicry was the major pattern of new vessel formation in the skeletal muscle and endothelium-dependent vessel formation in the abdominal cavity [84]. Difference in interstitial pressure offers a plausible explanation of why different mechanisms are in place. Melanoma cells developing in the dense structure of skeletal muscle require a more aggressive, enzyme-dependent mechanism for their growth and vessel formation. With regard to melanoma metastases in other sites, the number of microvessels in melanoma metastases in the brain was lower than the number seen in metastases to the breast or lung, and their diameter was intermediate when compared with these two types of metastases [85]. This finding was unexpected, since brain melanoma metastases are characterized by extremely frequent hemorrhage.

VEGF-A is the most potent stimulant of angiogenesis; however, data regarding its correlation with melanoma metastases are conflicting [32,86]. VEGF-A has multiple isoforms that are formed by alternative splicing of single mRNA [87,88]. One of the classes of isoforms of VEGF, VEGFxxxb, is known to have actual antiangiogenic properties [89]. VEGFxxxb expression is decreased in metastatic melanoma, which suggests switching from anti-angiogenic to proangiogenic isoforms during the formation of melanoma and metastasis [90].

Extravasation

Although melanoma is considered to metastasize mainly via the lymphatic route, the process of melanoma cells adhering to endothelial cells and the subsequent invasion into ECM has been studied extensively. Extravasation is the movement of cancer cells from the vessels to the surrounding tissue. Important parts of this process are adhesion to endothelial cells, and then degradation of components of the ECM (e.g., proteoglycans, including heparin sulphate). Migration of leukocytes through the endothelial cell layer involves interaction of β2-integrins LFA-1 or Mac-1 with their ligand ICAM-1. Most tumor cells do not express β2-integrins. Neutrophils may enhance the adhesion of melanoma cells to the endothelium and, subsequently, their extravasation. This is achieved by the binding of ICAM-1 onto melanoma cells and β2-integrins onto neutrophils [91]. This process is regulated by IL-8 that, in turn, is controlled by B-Raf [92]. B-Raf encodes a Ras-regulated kinase that regulates cell proliferation and is mutated in a specific site (glutamic acid for valine substitution at codon 600 in exon 15) [93]. On the other hand, some melanoma cells express other potential candidates that could mediate adhesion: αvβ3 or α4β1 integrins [94]. However, only highly metastatic melanoma cells expressing α4β1 bind to vascular cell-adhesion molecule (VCAM)-1 on endothelial cells as opposed to non-metastatic melanoma cells expressing similar levels of α4β1 [94]. This suggests an ancillary rather than primary role of this integrin in the adhesion. Lactadherin was recently shown to enhance phagocytosis of apoptotic melanoma cells [95]. This may have significance, not only in tumor development but also in adhesion of melanoma cells to endothelial cells. Both neutrophils and melanoma cells transiently express heparinase during invasion [96]. Production of metalloproteases by cancer cells is of paramount importance since tumor cells have to degrade collagens of the ECM in the setting of increasing interstitial pressure during tumor growth. It was shown that aggressive melanomas produce laminin-5 (Ln-5, γ2-chain), and membrane-type matrix metalloproteinase (MMP)-1, -2, -9 and -14 [97]. Ln-5 can then render poorly aggressive melanoma cells more aggressive. Melanoma cells metastasizing to the skeletal muscle overexpress MMP-2 and MMP-9, CK-18 and HIF-1α compared with melanoma cells metastasizing to the abdominal cavity [84]. Metalloproteases cleave triple helical collagen only at specific sites. Cathepsins B and L cleave collagen at specific extrahelical regions. Cathepsin K cleaves collagen both at intra- and extrahelical sites. Expression of all cathepsins have been documented in melanoma [98,99]. These enzymes not only cut collagens, but also elastin. Melanoma develops in the skin, an organ with a particular abundance of elastin. Elastin-derived peptides, such as VGVAPG or VAPG, bind to receptors on melanoma: galectin-3, integrin αVβ3 and the elastin-binding protein. Moreover, after binding of these peptides, melanoma cells become more aggressive and express more CXCR-4, MMP-2, MMP-3, VEGF-C, CD44, ICAM1 and neural cell adhesion molecule (NCAM) [100]. Extravasation is also promoted by autocrine production of VEGF-A acting on VEGFR-1 and -2 on melanoma cells [101]. Osteopontin, a gene overexpressed in melanoma as evidenced by microarray analyses, increases expression of several proteinases and may serve as an additional prognostic marker [102–104].

Evasion of immune surveillance

Melanoma cells develop mechanisms that prevent them from being attacked by immune cells. Natural killer (NK) cells are one of the most potent modes of organism defense against cancers. NKG2D ligands activate NKD2D (receptors) on NK cells. Intracellular retention of the NKG2D ligand MCH-I chain-related gene A (MICA) is responsible for evasion of melanoma cells from the effects of NK cells [105]. Melanoma cell proliferation is inhibited by cytokines, such as IL-2, IL-12, IFN-α, IFN-γ, TNF-α and IL-6. Oncostatin M is one of the families of IL-6-related cytokines that act through gp130 receptors and Janus kinase–signal transducers and activators of transcription pathways. Metastatic melanomas developed resistance to these cytokines through the modification receptor of oncostatin M. More specifically, hypoacetylation of the promoter of β-subunit rendered this receptor less responsive to oncostatin M [106].

Embolism

It is known that prothrombotic status promotes metastasis, whereas anticoagulation prevents its formation [107]. Neoplastic cells in circulation form complexes with leukocytes and platelets [108]. Platelets are thought to form a protective barrier that is an additional protective factor against the immune system [109]. In general, several molecules have been linked to metastasis formation, such as thrombin, tissue factor, P-selectin, fibrinogen and lypophosphatidic acid [108]. Congenital prothrombotic disorders predispose to the formation of lung metastases [110]. In one study, protease-activated thrombin receptor (PAR)-1 and not fibrin, tissue factor or VEGF correlated with occurrence of metastases [111]. Protease-activated thrombin receptor is a receptor with serpentine structure, activated through the cleavage of the extracellular amino terminus by thrombin. Cleaved terminus binds to the second extracellular domain of the receptor, resulting in an intracellular signal [112]. The platelet-specific receptor gp Ib-IX has a primary role in tethering the platelets to thrombus-forming surfaces [113]. gp Ib-IX, more specifically the α unit of gp Ib, is important in the formation of melanoma metastases in the lung [114]. Platelet factor ([PF]-4/CXCL4) has a role in thrombus formation [115]. A variant of PF-4, PF-4var/CXCL4L1, inhibits angiogenesis, development and metastasis of melanoma [116].

Angiotropism

Most models of metastasis assume that tumor cells intravasate into lymphatic or vascular circulation and then extravasate. Interestingly, an alternative concept has been developed with regards to melanoma metastasis [117]. It is known that melanoma spreads along nerves and skin appendages. As noted previously, the presence of melanoma cells in the circulation does not predict metastasis. It was noted that melanoma cells are located under endothelium entangled in matrix-containing laminin [118]. This concept suggests that melanoma cells travel along external surfaces of vessels rather than in their lumen (Figure 11). This model was called ‘extravascular migratory metastasis’ or ‘angiotropism’ [117]. γ1-aminin enhances melanoma pulmonary metastases [119]. Specific γ1-laminin-derived peptide, C16 (KAFDITYVRLKF), increased angiotropism without intravasation in the shell-less chick chorioallantoic membrane model [117]. This provides some evidence of angiotropism as a possible mechanism of melanoma spread.

Figure 11. Melanoma angiotropism.

Figure 11

Angiotropism, perivascular cuffing by melanoma cells of the external surface of vessels, is a recently described phenomenon [162], which has been shown to independently predict for local recurrence and in-transit metastasis [163]. The left panel shows the expansion of the media and adventitia of several small muscular vessels by melanoma cells. The right panel demonstrates a small vessel surrounded by a cuff of melanoma cells.

Melanocyte as the ‘source cell’ of melanoma

Melanoma is known to be more aggressive than most other cancers. Introduction of the Ras oncogene into normal melanocytes resulted in significantly more metastasizing melanomas than similar introduction into normal fibroblasts or epithelial cells [120]. This provides evidence that an intrinsic feature of the melanocyte might be responsible for the rapid development of metastatic disease. Since melanocytes are derived from the neural crest, they are characterized by expression of the motility-associated genes that not only mediate the neural crest but also tumor cell migration. Some of those genes are transcription factor Slug, endothelin receptor B, ERBB3, CD44 and Nodal [120,121]. Alternatively, the melanogenesis process that defines the melanocyte, might be the culprit [122]. Formation of melanin consists of transformation of l-tyrosine to melanin pigment through several oxidative–reduction reactions [123]. Melanogenesis thus forms oxidative environment and some of its intermediates (quinones and semiquinones) are directly toxic and mutagenic. Melanin scavenges biomolecules and oxygen. All these processes might significantly enhance the effects of typical oncogenes. Inhibition of melanogenesis should therefore decrease melanoma aggressiveness and act as an enhancer of current therapy protocols [124]. We have recently shown that the inhibition of melanogenesis by phenylthiourea and d-penicillamine enhanced cytoxicity of cyclophosphamide and IL-2-activated lymphocytes against melanoma cells [125].

Therapy

Treatment of melanoma in its early stages is predominantly surgical and consists of excision of the primary tumor with a 1–2-cm margin, and radical lymphadenectomy if the sentinel lymph nodes harbor metastasis. Patients with four or more positive lymph nodes, or melanoma extending beyond the lymph node capsule, may be treated with radiotherapy. Focal recurrent or in-transit tumors in the extremities can be treated with perfusion of limbs with hyperthermia and melphalan [72]. Patients with primary melanoma thicker than 2 mm with ulceration, thicker than 4 mm, regional lymph node involvement, and certainly those with metastatic disease can be offered an adjuvant therapy, possibly in a clinical trial setting with the use of IFN-α2b or IL-2. Alternative treatment options include combinations of dacarbazine (DTIC), tamoxifen, temozolomide and/or thalidomide. Several other options are either in research, preclinical or clinical trial phases [72,126].

So-called targeted melanoma therapy protocols (Table 2) focus on different antigens, receptors or signal transduction pathways-associated proteins such as BRAF, VEGFR, PDGFR, Raf kinases, mitogen-activated protein kinase kinase, Bcl-2, Kit, FLT-3, Cdk4/6, mTOR, PTEN–PI(3)K–Akt, Ras, NF-κB, αvβ3 integrin and heat-shock protein 90 [127]. Sorafenib (Nexavar®, BAY 43–9006) attacks the ATP-binding site of BRAF kinase and also CRAF, VEGFR-2, PDGFR-β, p38, fit-3 and c-kit [128]. Treatment with sorafenib alone resulted in stable disease in only 19% of the patients [129]. In Phase I/II trials, 54% of patients who received a combination of sorafenib with carboplatin and paclitaxel achieved remission lasting longer than 3 months [130]. However, a recent trial showed no difference in overall survival [131]. Treatment of patients with renal cell carcinoma or melanoma with a combination of sorafenib and IFN-α2b resulted in stable disease in 61.5% of patients [132]. Overall disease control rates to sorafenib in different trials ranged from 33 to 92% [133]. Monoclonal anti-CTLA-4 antibodies (MDX-010 and CP-675,206) target cytotoxic T-lymphocyte antigen-4. Cytotoxic T-cell-mediated anti-tumor activity consists of recognition of antigen associated with tumor by T-cell receptor (TCR) of cytotoxic T lymphocyte. This activity is enhanced by subsequent binding of CD80/86 to CD28 on T c. This second step can be impeded by CTLA-4 and, thus, inhibition of CTL-4 can be used as therapy [134]. In total, 11% of melanoma patients treated with anti-CTLA-4 antibody responded clinically [135]. Patients who received combination therapy with anti-CTLA-4 antibody and peptide vaccinations achieved a 17% response rate [136]. Combination therapy with anti-CTLA-4 and IL-2 achieved a 22% response rate [137]. Anti-BCL-2 antisense oligonucleotide (oblimersen sodium) inhibits antiapoptotic protein BCL-2 (Figure 12) [138]. Combination therapy with anti-BCL-2 antisense oligonucleotide and dacarbazine achieved a 13.5% overall response rate [139]. Monoclonal antibody against αVβ3 integrin (MEDI-522) targets a molecule important in endothelial cell proliferation and function that is also expressed in melanomas [140]. Patients treated with combination therapy of MEDI-522 and DTIC had a median survival of 12.6 months [141]. Stimulation of TLR9 activates plasmacytoid dendritic cells, thus inducing an innate immune response. Overall 15% of melanoma patients treated with TLR9 activating nucleotide (PF-3512676) achieved stable disease [142]. Midostaurin (PKC412A) inhibits several targets, including PKCα, VEGFR-2, Kit, PDGFR and FLT-3. In total, 12% of melanoma patients treated with this inhibitor achieved stable disease [143]. Angiozyme is a ribozyme that targets VEGFR-1 [144], a receptor related to angiogenesis. A total of 25% of melanoma patients treated with angiozyme achieved stable disease [145]. Addition of an anti-inflammatory agent, such as rofecoxib, increases modestly but significantly the effect of chemotherapy with trofosfamide [146]. There was an increase in 1-year survival rate of 9% and the HR (therapy augmented with rofecoxib versus chemotherapy alone) was 1.9 (95% CI: 1.17–3.06).

Table 2. Melanoma target therapies: summary of recent attempts of targeted melanoma therapies.

Drug Response* (%) Ref.
Anti-BRAF kinase 19–92 [127–131]
Anti-CTLA-4 antibodies 11–22 [132–135]
Anti-BCL-2 antisense oligonucleotide 13.5 [136]
Anti-αvβ3 antibody n/a [138–139]
TLR-9 activating nucleotide 15 [140]
PKCα inhibitor 12 [141]
Anti-VEGFR-1 ribozyme 25 [142,143]

Figure 12. Selection of therapy and phenotyping of melanoma metastases.

Figure 12

Determination of the phenotype and genotype of metastatic melanoma may play a new role in pathology to aid in the selection of targeted therapy. The antiapoptotic protein Bcl-2 is suspected to influence the treatment responsiveness of melanoma. The lack of Bcl-2 expression demonstrated in the melanoma metastasis in the right panel (lymphocytes are internal positive controls) has been associated with a higher response rate to chemoimmunotherapy in comparison to a diffuse and focal pattern of Bcl-2 expression found in the melanoma metastasis depicted in the left panel [164].

Since results of most clinical trials are very unsatisfactory, there is constant search for new molecular targets and treatment protocols. Potential targets include MCR-1 and CRH-R1 [147,148]. MCR-1 is a most important positive regulator of melanogenesis with stimulating α-MSH, adrenocorticotropin and inhibitory agouti ligands [123,149]. 177Lu-labeled DOTA conjugated to α-MSH prolonged survival of B16/F1 melanoma-bearing C57 mice [150]. CRH-R1 responds to CRH with stimulation of production and release of pro-opiomelanocortin-derived peptides by the pituitary and by the peripheral organs, including skin [151,152]. CRH inhibits proliferation of melanoma cells in vitro [153] and in vivo [154]. Other targets may include modification of steroid production and signaling [155–157] or other endocrine molecules [158,159].

Key issues

Expert commentary

In our opinion, one of the most important things yet to learn in melanoma metastasis biology are the mechanisms of homing of melanoma cells to target metastatic sites. Available data is rather scant and only partly based on experimental models. Pertinent clinical data in regards to mechanisms of routing of melanoma sites to different organs is practically nonexistent. Correlation of homing of melanoma cells with the homing of cells of immune origin is an entirely legitimate approach and has provided us some information on that aspect. Nevertheless, other receptor–ligand mechanisms should be explored. Searching for the presence of receptors on melanoma cells that would bind to tissue-specific ligands is one possible alternative. The other aspect of melanoma metastasis biology is the formation of metastatic cells. This does not have to be a Darwinian event as previously thought, but may occur through other mechanisms. Fusion of cancer cells with macrophages is a possible alternative that should be an object of more intense research and scrutiny in the melanoma community.

Five-year view

The current staging system of melanoma is effective in predicting patient prognosis. Nevertheless, the most important part of the diagnostic process (i.e., assessment of the presence of metastases in the sentinel lymph nodes) is still far from perfect. Evaluation of the expression of genes characteristic of melanoma cells, such as tyrosinase, in the potentially affected lymph nodes may be the most effective tool and become a diagnostic standard in the foreseeable future. Imaging techniques such as CT/PET are currently being intensively developed and if standardized, will become the most efficient tool to assess for the presence of distant metastases. Although traditional melanoma markers, such as S-100 or Melan-A, have a primary role in current diagnostic protocols, markers such as SPP1 and PRAME may become important ancillary tools. There is quite a lot of information about the interaction of melanoma cells with endothelium. Since melanoma cells tend to metastasize via the lymphatic route, there should be more efforts to elucidate the mechanism of interaction of melanoma cells with lymphatic vessels, such as survival in lymph, adhesion and extravasation. Migration of melanoma cells along the external walls of lymphatic vessels is an interesting alternative that should be assessed more closely. In spite of tremendous ongoing efforts, therapies directed at different molecular targets are largely unsuccessful. Combination therapies yield only modestly better effects. There are some efforts that focus on specific melanocyte-derived phenotype of melanoma cells. Melanocytes are not only resistant to UV light and toxins but melanoma cells are even more resistant to radio-, chemo- and biotherapies.

Acknowledgments

This work was supported by the National Institutes of Health grants AR047079 and AR052190 to AS.

Footnotes

Financial & competing interests disclosure: The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Contributor Information

Blazej Zbytek, Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, 930 Madison Avenue, Memphis, TN 38163, USA, Tel.: +1 901 448 6300, Fax: +1 901 448 6979, bzbytek@utmem.edu.

J Andrew Carlson, Department of Pathology and Laboratory Medicine, Albany Medical Center, 47 New Scotland Avenue, Albany, NY, USA, Tel.: +1 518 262 8099, Fax: +1 518 262 8092, carlsoa@mail.amc.edu.

Jacqueline Granese, Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, 930 Madison Avenue, Memphis, TN 38163, USA, Tel.: +1 901 448 6300, Fax: +1 901 448 6979, jackiegranese@yahoo.com.

Jeffrey Ross, Department of Pathology and Laboratory Medicine, Albany Medical Center, Albany, NY, 47 New Scotland Avenue, Albany, NY, USA, Tel.: +1 518 262 5461, Fax: +1 518 262 8092, rossj@mail.amc.edu.

Martin C Mihm, Jr, Dermatopathology Unit, Massachusetts General Hospital, 55 Fruit Street, WRN 225, Boston, MA 02114, USA, Tel.: +1 617 726 2967, Fax: +1 617 726 7474, mmihm@partners.org.

Andrzej Slominski, Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, 930 Madison Avenue, Memphis, TN 38163, USA, Tel.: +1 901 448 6300, Fax: +1 901 448 6979, aslominski@utmem.edu.

References

Papers of special note have been highlighted as:

• of interest

•• of considerable interes

Website